A phase I/II study (NCT03158389), which included co-treatment with RG7388 and radiotherapy on patients with newly diagnosed GBM with MGMT promoter demethylation, is ongoing to determine tolerability, PFS-6, and OS [324]. This evidence concerns the gene MGMT and glioblastoma.